Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Equity Income (2022 - 2023)

Zentalis Pharmaceuticals (ZNTL) has 2 years of Equity Income data on record, last reported at -$13.7 million in Q2 2023.

  • For Q2 2023, Equity Income fell 156.73% year-over-year to -$13.7 million; the TTM value through Mar 2024 reached -$13.7 million, up 18.63%, while the annual FY2023 figure was -$16.0 million, 1.65% up from the prior year.
  • Equity Income reached -$13.7 million in Q2 2023 per ZNTL's latest filing, down from -$2.3 million in the prior quarter.
  • Across five years, Equity Income topped out at -$1.8 million in Q1 2022 and bottomed at -$13.7 million in Q2 2023.